In the highly competitive field of immuno-oncology, one new target in particular has been capturing the attention of industry, investors and clinicians alike as a potential combination partner for PD-1/L1 checkpoint inhibitors: IDO.
Immune checkpoint inhibitors – including PD-1 and CTLA-4 – have emerged in force in oncology, sweeping aside old standards of...